← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck

FDA approvalNew or expanded indicationEndometrial cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with primary advanced or recurrent endometrial carcinoma; use with carboplatin and paclitaxel followed by pembrolizumab alone.

LAMPGEN ANALYSIS

Why it matters

This chemoimmunotherapy indication covers the disease regardless of mismatch repair status, with results reported separately by MMR group.

What research teams should watch

Capture MMR results and use separate treatment phases to reconcile chemotherapy completion and maintenance exposure.

PRIMARY RECORDS

Sources